This inventor holds 4 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 1 EPO patent. Top assignee: Lek Pharmaceuticals D.d.. Active years: 2009-2013.
Company Filing History:
Years Active: 2009-2013
Title: Barbara Podobnik: Innovator in Pharmaceutical Composition
Introduction
Barbara Podobnik is a prominent inventor based in Ljubljana, Slovenia. She has made significant contributions to the field of pharmaceuticals, particularly in the development of stable compositions that enhance the efficacy of treatments. With a total of 4 patents to her name, her work is recognized for its innovative approach to pharmaceutical formulations.
Latest Patents
Among her latest patents is a surfactant-free stable pharmaceutical composition comprising granulocyte-colony stimulating factor. This invention provides a new stable pharmaceutical composition of granulocyte-colony stimulating factor (G-CSF), which is crucial for various medical applications. Another notable patent is a pharmaceutical composition comprising an active principal and sulphobetaine, which relates to a non-detergent sulphobetaine (NDSB) that enhances the stability of pharmaceutical formulations.
Career Highlights
Barbara is currently associated with Lek Pharmaceuticals D.d., a leading pharmaceutical company in Slovenia. Her role at Lek Pharmaceuticals has allowed her to focus on innovative research and development, contributing to the advancement of pharmaceutical sciences.
Collaborations
Throughout her career, Barbara has collaborated with esteemed colleagues such as Viktor Menart and Vladka Gaberc Porekar. These collaborations have fostered a dynamic environment for innovation and have led to the successful development of her patented technologies.
Conclusion
Barbara Podobnik stands out as a key figure in the pharmaceutical industry, with her innovative patents paving the way for advancements in drug formulation. Her contributions continue to impact the field positively, showcasing her dedication to improving healthcare solutions.